Podcasts about screening test

In this episode of the Celebrate Kids podcast, Dr. Kathy Koch discusses the importance of mental health in teenagers and young children. You're introduced a new screening test that can help detect early signs of mental health disorders and provide early intervention. Dr. Kathy then highlights the significance of early intervention and shares that around 50 percent of lifetime mental health conditions start at the age of 14. She  acknowledges that mental health is a concern for most parents and encourages creating a rhythm for mental health screenings. In closing, Dr. Kathy gives important tips for parents as they care for their kids' mental health

Do you know that prostate cancer is the second most prevalent cancer in American men, following skin cancer? A new diagnosis of prostate cancer occurs every two minutes. We are delighted to partner with Oxford Biodynamics for today's episode with Dr. Robert Heaton, who joins us to discuss a ground-breaking new prostate cancer screening test that predicts the risk of prostate cancer with 94% accuracy, using a simple blood test. Dr. Heaton is a board-certified pathologist. He completed his medical training at Georgetown University and then spent the next twenty years in the US Navy. After finishing his residency training in pathology, Dr. Heaton became the Director of Laboratory and Clinical Support Services for the National Naval Medical Center before joining various hospital pathology labs and life sciences companies. He is currently the Laboratory Medical Director for Oxford Biodynamics at their CLIA-certified clinical lab in Maryland, where he oversees the clinical operations of their liquid biopsy blood tests. In today's episode, we dive into the details of the innovative EpiSwitch Prostate Screening test, known as the PSE, designed to confirm the presence of prostate cancer, whether symptoms are present or not. This technological advancement is a game-changer! It empowers urologists by providing a precise tool to assess whether a patient should undergo a biopsy or opt for continued monitoring. Stay tuned to learn how this simple yet powerful tool streamlines the screening process for men struggling with prostate cancer. Disclaimer: The Prostate Health Podcast is for informational purposes only. Nothing in this podcast should be construed as medical advice. By listening to the podcast, no physician-patient relationship has been formed. For more information and counseling, you must contact your personal physician or urologist with questions about your unique situation.   Show Highlights: At what age should men start getting checked for prostate cancer?  What the screening for prostate cancer typically entails The importance of establishing a baseline to monitor how PSA changes over time Dr. Heaton dives into the details of the EpiSwitch PSA test How men can access the EpiSwitch PSA test Dr. Heaton discusses the accuracy of the EpiSwitch PSA test What is the expected turnaround time for the EpiSwitch PSC test results? Dr. Heaton explains the role of the Epi Switch PSA test in different scenarios The revolutionary EpiSwitch Prostate Screening test has remarkable accuracy in predicting prostate cancer risk through a simple blood test. It holds immense promise for men battling prostate cancer by providing urologists with a precise diagnostic tool and offering a streamlined approach for patients facing the complexities of prostate cancer. Links: Follow Dr. Pohlman on Twitter and Instagram - @gpohlmanmd Get your free What To Expect Guide (or find the link on our podcast website)   Join our Facebook group  Follow Dr. Pohlman on Twitter and Instagram  Go to the Prostate Health Academy to sign up.  You can access Dr. Pohlman's free mini webinar, where he discusses his top three tips to promote men's prostate health, longevity, and quality of life here. Oxford BioDynamics: Website LinkedIn  Facebook Twitter: @oxbiodynamics and #OBD Instagram: @oxbiodynamics YouTube: @oxfordbiodynamics PSE: Website LinkedIn Facebook Twitter: (@94percent_com) Instagram: (@get_the_pse)

Resources: and so much more at https://www.womenshealthmelbourne.com.au/blog Find us on Instagram - @knockeduppodcast Join our community! Follow Women's Health Melbourne on Facebook and Instagram (@womenshealthmelbourne), and follow Dr Raelia Lew on Instagram (@drraelialew). Have a question about women's health? Is there a specific topic you'd like us to cover? Email podcast@womenshealthmelbourne.com.au. We keep all requests anonymous. Women's Health Melbourne is a holistic care precinct, for more information about the work we do click here. Hosts: Dr Raelia Lew and Jordi MorrisonSee omnystudio.com/listener for privacy information.

Editor's Summary by Anne Rentoumis Cappola, MD, ScM, Associate Editor of JAMA, the Journal of the American Medical Association, for the October 10, 2023, issue. Related Content: Audio Highlights

Should Bert take the screening test that could possibly, MAYBE tell him if he has a chance of having cancer in the future? What do you think? Learn more about your ad choices. Visit megaphone.fm/adchoices

“It is better to be safe than sorry. My call to action for Aboriginal Mob across Australia is: don't be complacent; get the kit when it comes to you; do it and send back… Bowel cancer is one of the easiest cancers to treaty if it is done early.” - Aunty Jill Gallagher.

Maggie Malone, CEO of Certior Health and Dr Nick Flynn, GP and Chief Medical Officer of Certior Health joined Anton Savage who was filling in for Pat to discuss the new cancer screening test.

A new campaign featuring Waanyi Gangalidda and Erub man Trevor Tim is encouraging Aboriginal and Torres Strait Islander peoples to stay strong and healthy by doing a free bowel cancer screening test every 2 years from the age of 50. “I think it's very important that our people, our mob, do the free test. We're talking about leading the way for our people, we need to close the gap and we need our mob to be living longer,” Trevor Tim.

The gold-standard antibiotic screening test has fundamental issues, but UCSB researchers have developed a new test -- one that's much more accurate. The study's lead author speaks with KCSB's Joyce Chi on why the healthcare industry can't let go of the gold-standard test, and on what the new test means for fighting antibiotic resistance.

Listen to the SBS Sinhala radio interview with Dr.Lakmini Busnayaka from Brisbane explaining about the eligibility criteria for mammogram test in Australia and the must known facts about diagnostic test. - පියයුරු පිළිකා කල් ඇතුව හඳුනාගැනීම සඳහා භාවිතා කරන මැමෝග්‍රම් පරීක්ෂණය පිළිබඳ ඔබ දැන ගත යුතුම වැදගත් තොරතුරු දැන ගන්න මේ ගුවන්විදුලි සාකච්ඡාවට සවන් දෙන්න.

Avrio Genetics (267-329-9319) in Allentown, PA helps you determine whether you're at risk for fibromyalgia. We've recently launched a new genetic screening test for the condition. Learn more at https://avriogenetics.com (https://avriogenetics.com)

In unserer Nachmittagsfolge begrüßen wir heute Meik Baumeister, Co-Founder und CEO von Cardisio, und sprechen über die Finanzierungsrunde i.H.v. 3,5 Millionen Euro. Cardisio ist ein Mobile-Health-Tech-Unternehmen, das KI für den - Unternehmensangaben zufolge - weltweit ersten und einzigen nicht-invasiven Screening-Test für die Früherkennung von Herzkrankheiten nutzt. Menschen mit Herzerkrankungen sind in der Regel bis zum Auftreten eines Herzinfarkts symptomfrei. Der Cardisiographie-Test soll Herzkrankheiten frühzeitig erkennen und so eine vorbeugende Behandlung ermöglichen. Und das, bevor es zu einem potenziell tödlichen Herzinfarkt kommt. Die Vorteile einer Cardisiographie ist die einfache Handhabung, die Genauigkeit und die kostengünstige Durchführung. Eine Gruppe privater Investoren hat sich jetzt mit insgesamt 3,5 Millionen Euro an dem Startup beteiligt. Zu den individuellen Geldgebern gehören Jim Davidson, der Mitbegründer von Silver Lake, und Shawn O'Neill, Geschäftsführer bei Silver Lake Waterman. Ergänzt wird die Runde durch mehrere neue und bereits existierende Privatinvestoren aus den USA und Deutschland. Wenn auch Du Dein Lieblingstool bewerten willst, schreibe eine Review auf OMR Reviews. Dafür erhältst du einen 20€ Amazon Gutschein. https://moin.omr.com/insider

I know Podcasts are meant to be about true crime, I know, not paps smears and pregnancy! This topic is too important not to soar up the podcast charts! In today's super-fast episode I talk about the Cervical Screening Test (CST) its importance and the facts about CST and pregnancy.*Spoiler alert - it is safe to have a CST when you're pregnant*The benefits of being on top of CST ( the new form of pap smear) far outweigh the uncomfortable bits.  In the past five years, the way CST are undertaken have changed so CST is a really good topic to add to your list of questions to ask your GP.For information on how a CST works visit herehttps://www.health.gov.au/initiatives-and-programs/national-cervical-screening-program/getting-a-cervical-screening-test/how-cervical-screening-worksSome extra information from The Royal Australian and New Zealand College of Obstetricians and Gynaecologists https://ranzcog.edu.au/womens-health/patient-information-resources/cervical-screening-in-australiaThis episode is fact-checked and supported by www.familyhq.com.au - thanks Liz and Sarah.For more on the suite set, please visit us at https://www.thesuiteset.com/pages/our-gift-to-you

Troy Chats with Katanning Mum Rachel on Changes to The WA Infant Screening See omnystudio.com/listener for privacy information.

Australian News: 14 May 2021 – Fridat Read by Selvi - ஆஸ்திரேலிய செய்திகள்: 14 மே 2021 வெள்ளிக்கிழமை வாசித்தவர்: செல்வி

In this latest SBS Hindi News bulletin: Five commissioners to lead Victoria's Australia-first inquiry into injustices committed against Indigenous people; Conflict in Gaza escalates further; Australia's Indian Premier League contingent could return home as early as this weekend and more.

Health workers at the frontline of fighting terrible rates of cervical cancer among Māori say a new, easier test, will save lives but isn't a one-stop fix. The government will introduce a type of swab to test for the HPV virus which causes 99 percent of cervical cancers. Women can do it themselves and it's hoped it will rein in cases, particularly among Māori women, who are two and a half times more likely to die from the disease. Health correspondent Rowan Quinn reports.  

Health workers at the frontline of fighting terrible rates of cervical cancer among Māori say a new, easier test, will save lives but isn't a one-stop fix. The government will introduce a type of swab to test for the HPV virus which causes 99 percent of cervical cancers. Women can do it themselves and it's hoped it will rein in cases, particularly among Māori women, who are two and a half times more likely to die from the disease. Health correspondent Rowan Quinn reports.  

The director of Te Tātai Hauora o Hine, the Centre for Women's Health Research at Victoria University, wants a less invasive cervical screening test rolled out as soon as possible. The government has announced a $55 million funding boost to make the test available, but not until 2023. Currently there are 400,000 New Zealanders who are not getting regular smear tests.  Susie Ferguson spoke to Te Tātai Hauora o Hine founder Bev Lawton.  

The director of Te Tātai Hauora o Hine, the Centre for Women's Health Research at Victoria University, wants a less invasive cervical screening test rolled out as soon as possible. The government has announced a $55 million funding boost to make the test available, but not until 2023. Currently there are 400,000 New Zealanders who are not getting regular smear tests.  Susie Ferguson spoke to Te Tātai Hauora o Hine founder Bev Lawton.  

We're always looking for easier ways to detect cancer earlier. It gives our patients the opportunity for better prognoses.    Today we're talking about one of the new ways to detect cancer early. It's called the Nu.Q Cancer Screening Test, and it was developed by a joint effort from a company called Volition and Texas A&M College of Veterinary Medicine.   Joining me today is Dr. Heather Robles, who led the research at Texas A&M in order to make this test possible.    Dr. Heather Robles is a board-certified veterinary oncologist and Chief Medical Officer of Volition Veterinary Diagnostics Development. She is also the Professor of Oncology at the Texas A&M College of Veterinary Medicine & Biomedical Sciences, along with the Assistant Department Head of Research and the Dr. Fred A. and Vola N. Palmer Chair in Comparative Oncology.    Join us as we spread the word about this test and answer as many questions as we can in this episode.    Resources Mentioned: Volition Veterinary - Nu.Q Cancer Screening Test  Texas A&M GI Lab - Sample Processing/Collection Information    Full show notes and links mentioned in the episode are available at www.caninecanceracademy.com/podcast-ep-35   Don’t forget to say hello on Instagram @thecaninecaneracademy and on Facebook Canine Cancer Academy

The Newborn Screening Test is a quick, safe and effective way to identify babies at risk of certain serious conditions. Screening is the only way to identify affected babies early as there may be no signs or symptoms of illness at birth. By the time affected babies show symptoms, their development or health may already be impaired. Early diagnosis allows early treatment or management to prevent or reduce complications. Follow us on Instagram: https://www.instagram.com/yourekiddingright.pod/ and  Facebook: https://www.facebook.com/yourekiddingrightpod-107273607638323/ Our email is yourekiddingrightpod@gmail.com Make sure you hit SUBSCRIBE/FOLLOW so you don’t miss out on any pearls of wisdom and RATE if you can to help other people find us! (This isn’t individual medical advice, please use your own clinical judgement and local guidelines when caring for your patients)

What's the verdict, Jonesy? See omnystudio.com/listener for privacy information.

The rollout of a cervical screening test that patients can do themselves has been delayed again, with doctors saying some people will die unnecessarily as a result. The alternative to the current speculum test was meant to be introduced next year - after already being delayed three years. Professor Beverley Lawton is Director of Te Tatai Hauora o Hine, the Centre for Women's Health Research, at Victoria University of Wellington and speaks to Corin Dann.

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2020.07.21.214395v1?rss=1 Authors: Milne, A. E., Bianco, R., Poole, K. C., Zhao, S., Billig, A. J., Chait, M. E. Abstract: Online experimental platforms can be used as an alternative, or complement, to lab-based research. However, when conducting auditory experiments via online methods, the researcher has limited control over the participants' listening environment. We offer a new method to probe one aspect of that environment, headphone use. Headphones not only provide better control of sound presentation but can also "shield" the listener from background noise. Here we present a rapid (< 3 minute) headphone screening test based on Huggins Pitch (HP), a perceptual phenomenon that can only be detected when stimuli are presented dichotically. We validate this test using a cohort of "Trusted" online participants who completed the test using both headphones and loudspeakers. The same participants also trialled a widely used headphone test (AP test; Woods et al., 2017). We demonstrate that compared to the AP test, the HP test has a higher selectively for headphone users, rendering it as a compelling alternative to the existing screening method. Overall, the new HP test correctly detects 80% of headphone users and has a false positive rate of 20%. Moreover, we demonstrate that there is little overlap between participants who pass both HP and AP tests over loudspeakers. Therefore, combining the two tests can lower the false positive rate to ~7% (but at the expense of an increased false negative rate). This should be useful in situations where headphone use is particularly critical (e.g. dichotic or spatial manipulations). An implementation of the new test is available with JavaScript and through Gorilla (gorilla.sc). Copy rights belong to original authors. Visit the link for more info

JEST allow applicants who wish to join premium institutes for natural and life sciences program for Ph.D. and Integrated Ph.D. i.e. MSc + Ph.D. During the last podcast, we got introduced to one such premium institute i.e. Tata Institute of Fundamental Research. So, for the students who wish to choose research and become leading scientists they must know these institutes and the kind of program they offer and their eligibility criteria. So, if your broad interests are Physics, Chemistry, Biology, Mathematics, Neurosciences, computer sciences then you must look at JEST and the participating institutes. Therefore, let me begin by introducing these participating institutes and maybe a little bit more about them. This podcast explore on all the participating institutes and their eligibility criteria. --- Send in a voice message: https://anchor.fm/vijay-sonawane/message

In this VETgirl online veterinary CE podcast, we review whether cardiac troponin I is an accurate screening test for the diagnosis of Hypertrophic Cardiomyopathy (HCM) in cats. Hypertrophic cardiomyopathy is defined as concentric hypertrophy of the left ventricle in the absence of any other identifiable cause, in particular systemic hypertension and hyperthyroidism in cats.

In this VETgirl online veterinary CE podcast, we review whether cardiac troponin I is an accurate screening test for the diagnosis of Hypertrophic Cardiomyopathy (HCM) in cats. Hypertrophic cardiomyopathy is defined as concentric hypertrophy of the left ventricle in the absence of any other identifiable cause, in particular systemic hypertension and hyperthyroidism in cats.

You have the option to screen for a number of genetic disorders in pregnancy. How are these tests performed and what can be discovered? Dr. Julia Cormano explains the difference between screening and diagnostic testing, what can be learned from a blood test, as well what to expect from chorionic villus sampling and amniocentesis. Series: "Motherhood Channel" [Health and Medicine] [Show ID: 33874]

You have the option to screen for a number of genetic disorders in pregnancy. How are these tests performed and what can be discovered? Dr. Julia Cormano explains the difference between screening and diagnostic testing, what can be learned from a blood test, as well what to expect from chorionic villus sampling and amniocentesis. Series: "Motherhood Channel" [Health and Medicine] [Show ID: 33874]

You have the option to screen for a number of genetic disorders in pregnancy. How are these tests performed and what can be discovered? Dr. Julia Cormano explains the difference between screening and diagnostic testing, what can be learned from a blood test, as well what to expect from chorionic villus sampling and amniocentesis. Series: "Motherhood Channel" [Health and Medicine] [Show ID: 33874]

You have the option to screen for a number of genetic disorders in pregnancy. How are these tests performed and what can be discovered? Dr. Julia Cormano explains the difference between screening and diagnostic testing, what can be learned from a blood test, as well what to expect from chorionic villus sampling and amniocentesis. Series: "Motherhood Channel" [Health and Medicine] [Show ID: 33874]

You have the option to screen for a number of genetic disorders in pregnancy. How are these tests performed and what can be discovered? Dr. Julia Cormano explains the difference between screening and diagnostic testing, what can be learned from a blood test, as well what to expect from chorionic villus sampling and amniocentesis. Series: "Motherhood Channel" [Health and Medicine] [Show ID: 33874]

You have the option to screen for a number of genetic disorders in pregnancy. How are these tests performed and what can be discovered? Dr. Julia Cormano explains the difference between screening and diagnostic testing, what can be learned from a blood test, as well what to expect from chorionic villus sampling and amniocentesis. Series: "Motherhood Channel" [Health and Medicine] [Show ID: 33874]

You have the option to screen for a number of genetic disorders in pregnancy. How are these tests performed and what can be discovered? Dr. Julia Cormano explains the difference between screening and diagnostic testing, what can be learned from a blood test, as well what to expect from chorionic villus sampling and amniocentesis. Series: "Motherhood Channel" [Health and Medicine] [Show ID: 33874]

You have the option to screen for a number of genetic disorders in pregnancy. How are these tests performed and what can be discovered? Dr. Julia Cormano explains the difference between screening and diagnostic testing, what can be learned from a blood test, as well what to expect from chorionic villus sampling and amniocentesis. Series: "Motherhood Channel" [Health and Medicine] [Show ID: 33874]

Don't let embarrassment from doing a cervical cancer screening test kill you. - Txhob cia txoj kev txaj muag ua rau koj tas sim neej vim tsis xav mus sim seb puas puas yog koj mob kab mob cancer tsev me nyuam!

  I was intrigued to speak with Dr. Herbert Brill of William Osler Health System regarding the study he did with other health care professionals on the efficacy of the DGP blood test with children referred for further consultation in screening for celiac disease.  The study focussed on children with a negative TTG test and a positive DGP test.  The study concluded the test was not useful in screening children for celiac disease in the general population.  You can find an article about the study on the William Osler Health System website or at the following link – http://bit.ly/DGPTestStudy This study was brought to my attention by a post from Ellen Bayens of The Celiac Scene.  You can subscribe to her newsletter at www.theceliacscene.com.  Thanks Ellen! Sue's Websites and Social Media – Podcast https://acanadianceliacpodcast.libsyn.com Podcast Blog – https://www.acanadianceliacblog.com Facebook - @acanadianceliacpodcast Twitter – CeliacPodcastCA Email – acdnceliacpodcast@gmail.com Baking Website – https://www.suesglutenfreebaking.com Instagram - @suesgfbaking YouTube - https://www.youtube.com/playlist?list=PLUVGfpD4eJwwSc_YjkGagza06yYe3ApzL      (search Sues Gluten Free Baking) Email – sue@suesglutenfreebaking.com Other Podcast – Gluten Free Weigh In – https://glutenfreeweighin.libsyn.com

  I was intrigued to speak with Dr. Herbert Brill of William Osler Health System regarding the study he did with other health care professionals on the efficacy of the DGP blood test with children referred for further consultation in screening for celiac disease.  The study focussed on children with a negative TTG test and a positive DGP test.  The study concluded the test was not useful in screening children for celiac disease in the general population.  You can find an article about the study on the William Osler Health System website or at the following link – http://bit.ly/DGPTestStudy This study was brought to my attention by a post from Ellen Bayens of The Celiac Scene.  You can subscribe to her newsletter at www.theceliacscene.com.  Thanks Ellen! Sue's Websites and Social Media – Podcast https://acanadianceliacpodcast.libsyn.com Podcast Blog – https://www.acanadianceliacblog.com Facebook - @acanadianceliacpodcast Twitter – CeliacPodcastCA Email – acdnceliacpodcast@gmail.com Baking Website – https://www.suesglutenfreebaking.com Instagram - @suesgfbaking YouTube - https://www.youtube.com/playlist?list=PLUVGfpD4eJwwSc_YjkGagza06yYe3ApzL      (search Sues Gluten Free Baking) Email – sue@suesglutenfreebaking.com Other Podcast – Gluten Free Weigh In – https://glutenfreeweighin.libsyn.com

Questa sera a POP si parla di Futuro Anteriore, spettacolo di Produzione Ferrara Off, con la drammaturga Margherita Mauro e il regista Giulio Costa. fra gli interpreti anche Matilde, per uno spettacolo sul futuro della terza età che sarà in prima Nazionale questo weekend a Ferrara Off http://www.ferraraoff.it/futuro-anteriore/

There is no golden standard on preparing a screening test for interpreting students. You are supposed to find your own way. In this article I would like to share my approach. Screening test is a must: For one, not every student can become a simultaneous interpreter. Giving false hopes to young minds will only increase their desperation before your realize it is too late. Second, interpreter trainers are usually professional interpreters and they do not have the time and energy needed […]

In this episode we talk about the health effects of Chocolate, Diabetes, a Screening Test and spin the Wheel of Medicine. We hope you join us as we dive deep into medicine so you don't have to. We present the best studies and research in easy to understand and entertaining ways. We gladly accept show topics and ideas from our listeners.

Dogs (and cats) having a crisis as a result of hypoadrenocorticism (Addisonian crisis) can be in a life-threatening state and this represents one of the true small animal emergencies. Stabilisation of these patients starts with appropriately aggressive intravenous fluid therapy as the first priority and treatment for clinically significant hyperkalaemia and hypoglycaemia may also be needed very early on. Intravenous glucocorticoids are typically then required to continue stabilisation. In this episode I discuss ten talking points relating to canine hypoadrenocorticism, namely: “The Great Pretender” Likely Genetic Basis Aldosterone may be low in ‘atypical’ cases Hypoglycaemia may be severe Bradycardia is not always present and not just due to hyperkalaemia ACTH stimulation test provides definitive diagnosis Single resting plasma cortisol may be useful for screening – but limited role in emergencies? Intravenous fluid therapy Client communication and education Prognosis is good with appropriate management – yey!   Click Here For Your FREE Copy of a Transcript of This Episode   PAPERS that helped inspire some of the content for this episode are: Baumstark ME, Sieber-Ruckstuhl NS, Mϋller C, et al. Evaluation of Aldosterone Concentrations in Dogs with Hypoadrenocorticism. J Vet Intern Med 2014; 28:154–159. (Open access online) Boag AM, Catchpole B. A Review of the Genetics of Hypoadrenocorticism. Topics in Companion Animal Medicine 2015 (Accepted manuscript pending publication). Bovens C, Tennant K, Reeve J, Murphy KF. Basal Serum Cortisol Concentration as a Screening Test for Hypoadrenocorticism in Dogs. J Vet Intern Med 2014; 28:1541–1545. (Open access online) Lennon EM, Boyle TE, Hutchins RG, et al. Use of basal serum or plasma cortisol concentrations to rule out a diagnosis  of hypoadrenocorticism in dogs:  123 cases (2000–2005). J Am Vet Med Assoc 2007; 231:413–416. (Abstract)

Sat, 21 Jul 2012 12:00:00 +0100 https://edoc.ub.uni-muenchen.de/17336/ https://edoc.ub.uni-muenchen.de/17336/1/Roos_Anja.pdf Roos, Anja Alexandra

New Screening Test for Antibiotic Residue

Audio Journal of Medicine, August 8th 2007 Visual Cervix Cancer Screening Test: Cheap and Effective in the Developing World REFERENCE: Lancet 2007;370:398-406 RENGASWAMY SANKARANARAYANAN, International Agency for Research on Cancer, Lyon An inexpensive visual cervix cancer-screening test has proved its worth in India according to a publication in the Lancet. Inspecting the cervix visually after applying 4% acetic acid can reduce the incidence and mortality from cervical cancer in developing countries. Nicola Solomon interviewed Rengaswamy Sankaranarayanan.

Hintergrund: Die konventionelle Weiss-auf-Weiss-Perimetrie zählt zum Goldstandard der Glaukom-Diagnostik. Der Verlust achromatischer Kontrastempfindlichkeit ist aber als sensorischer Ausfall ein Spätsymptom und markiert den Beginn einer lokalen Erblindung. In diversen Studien konnte nachgewiesen werden, dass ein Verlust an chromatischer Kontrastempfindlichkeit im kurzwelligen Bereich des Farbspektrums perimetrischen Gesichtsfelddefekten vorausgehen kann. Eine quantitative Bestimmung peripherer Farbkontrastempfindlichkeit erlaubt der Arden-Computergraphik-Farbtest. Ziel dieser Querschnittsstudie war zum einen, Unterschiede in der peripheren Farbkontrast-Sensitivität zwischen einer größeren Gruppe von Glaukom-Patienten (n=50), sogenannten präperimetrischen Diagnosegruppen (Patienten mit okulärer Hypertension, Patienten mit V.a. Glaukom, n=41) und augengesunden Patienten (n=19) zu finden, und zum anderen die Bestimmung von Zusammenhängen zwischen peripheren Farbkontrast-Verlusten im kurzwelligem Bereich (Tritanachse) und zu diesem Zeitpunkt gegebenenfalls bestehenden Pathologien der Papillenmorphologie. Hierfür wurde sowohl der Mittelwert der Farbkontrastempfindlichkeit der einzelnen Quadranten, als auch die Farbkontrastempfindlichkeit eines einzelnen Quadranten (hier „Field Low Left“) mit den entsprechenden HRT II-Parametern (global oder ein einzelner Sektor) korreliert. Patienten und Methodik: Insgesamt wurden 110 Patienten in die Studie miteingeschlossen, und in die Diagnosegruppen „Glaukom“ (n=50), „V.a. Glaukom“ (n=26), „OCH“ (n=13) und „Augengesund“ (n=21) eingeteilt. Bei allen Patienten wurde eine Messung mit dem HRT II zur Erhebung quantitativer Papillen-Mekmale, und der Arden-Computergraphik-Farbtest durchgeführt. Darüber hinaus erfolgte jeweils eine Gesichtsfelduntersuchung, eine Visusbestimmung, eine allgemeine Anamnese, eine ausführliche Medikamentenanamnese und die Bestimmung der im bisherigen Krankheitsverlauf maximalen Tensiowerte. Die Papillenmorphologie wurde anhand qualitativer Merkmale von einem erfahrenen Untersucher in folgende Gruppen eingeteilt: „glaukomatöser Papillenbefund“, „grenzwertiger Papillenbefund“ und „unauffälliger Papillenbefund“. Nichtparametrische Tests: Im Kruskall-Wallis-Test zeigten die Variablen „Field mean“ und „Field LowL“ einen signifkanten Unterschied (p=0,039 bzw. p=0,023) zwischen den Diagnosegruppen. Im Mann-Whitney-Test erfüllen „Field LowL“-Werte die Kriterien einer Zusammenfassung 66 Signifikanz-Adjustierung und unterscheiden sich zwischen den Diagnosgruppen „Glaukom“ und „Augengesund“ statistisch signifkant (p=0,006). Ergebnisse der bivariaten Korrelation: Sowohl im Gesamtkollektiv, als auch in der Diagnosegruppe „Glaukom“ zeigte der Farbkontrast-Schwellenwert des unteren linken Quadranten („Field LowL“) im Unterschied zum Mittelwert der Farbkontrast-Schwellenwerte der Einzel-Quadranten („Field mean“) die stärkeren und häüfigeren Zusammenhänge zur Papillenmorphologie. In der Gruppe „Glaukom“ zeigte „Field LowL“ statistisch signifikante Zusammenhänge zu den meisten stereometrischen Parametern des HRT II: „cup area“ (r=0,547, p=0,000), „rim area“ (r=0,456, p=0,001), „cup/disc area ratio“ (r=0,525, p=0,000), „rim/disc area ratio“ (r=0,525, p=0,000), „cup volume“ (0,453, p=0,001), „rim volume“ (r=0,409, p=0,003), „height variation contour (r=0,38, p=0,006), „cup shape measure“ (r=0,345, p=0,012), „mean RNFL thickness“ (r=0,404, p=0,004) und „RNFL cross sectional area“ (r=0,381, p=0,006). In den präperimetrischen Diagnosegruppen „V.a. Glaukom“ und „OCH“ konnte nur in der „OCH“-Gruppe ein statistisch hochsignifikanter Zusammenhang (r=0,764, p=0,001) zwischen „Field LowL“ und dem stereometrischen Paramter „height variation contour“ gefunden werden. Ergebnisse der partiellen Korrelation: Bei Konstanthalten des Einflusses der Variable „age“ in der Glaukom-Gruppe zeigt „Field mean“ einen moderaten, statistisch signifikanten Zusammenhang zu den HRT-II-Parametern „height variation contour“ (r=0,348, p=0,008) und „CLM temporal-inferior“ (r=0,371, p=0,005). Bei Herauspartialisieren der Variable „disc area“ konnten alle in der bivariaten Korrelation gefundenen Zusammenhänge beibehalten werden. Bei Konstanthalten des Einflusses der mittleren Defekttiefe der Gesichtsfelduntersuchung („MD in dB“) zeigten sich keine statistisch signifikanten Zusammenhänge. Im Unterschied dazu zeigte der Quadranten-Schwellenwert „Field LowL“ in der Glaukom-Gruppe sowohl bei Konstanthalten des Einflusses des Alters, als auch der Papillengröße, als auch der mittleren Defekttiefe der Gesichtsfeld-Untersuchung statistisch signifikante Zusammenhänge zu allen auch in der Pearson-Korrelation gefundenen stereometrischen HRT-II-Parametern, wobei die Zusammenhangs-Stärke bei Herauspartialisieren von „disc area“ und „MD in dB“ schwächer ausfiel als in der bivariaten Korrelation; bezüglich der Kontrollvariable „MD in dB“ sind es: „cup area“ (r=0,457, p=0,001), „rim area“ (r=0,290, p=0,033), „cup/disc area ratio“ (r=0,419, p=0,003), „rim/disc area ratio“ (r=0,419, p=0,003), „cup volume“ (0,333, p=0,017), „rim volume“ (r=0,319, p=0,021), „height variation contour (r=0,304, p=0,027), „cup shape measure“ (r=0,260, Zusammenfassung 67 p=0,05), „mean RNFL thickness“ (r=0,411, p=0,004) und „RNFL cross sectional area“ (r=0,354, p=0,012). Der in der bivariaten Korrelation in der „OCH“-Gruppe gefundene, starke Zusammenhang zwischen „Field LowL“ und dem stereometrischen Paramter „height variation contour“ zeigte sich auch bei Herauspartialisieren des Alters und der mittlerern Defekttiefe der Gesichtsfeld-Untersuchung: r=0,686, p=0,01 bzw. r=0,794, p=0,002, jedoch nicht bei Herauspartialisieren der Variablen „disc area“ (r=0,001, p=0,499). Der überwiegende Teil der in den präperimetrischen Diagnosegruppen gefundenen Zusammenhänge zeigte sich jedoch statistisch nicht signifikant. Ergebnisse der Regressionsanalyse: Sowohl nichtstereometrische Parameter wie Alter, Augeninnendruck und Ergebnisse der Gesichtsfelduntersuchung, als auch die stereometrischen Parameter des Heidelberg-Retina-Tomographen-II zeigen einen statistisch signifikanten Einfluss auf die Ergebnisse des Computergraphik-Farbtests. Während der Einfluss von nichtstereometrischen Parametern einen stärkeren Einfluss auf die Variable „Field mean“ als auf die Variable „Field LowL“ aufweist (r2=0,445, p=0,000 versus r2=0,359, p=0,001), verhält es sich mit den stereometrischen HRT-II-Parametern umgekehrt: Sie zeigen den stärkeren Einfluss auf die Variable „Field LowL“ (r2=0,603, p=0,000 versus r2=0,188, p=0,048). Schlussfolgerung: Die Diagnose „Glaukom“ setzt sich aus den Ergebnissen unterschiedlicher Untersuchungen zusammen. Zu den Eckpfeilern der Glaukom-Diagnostik zählen Papillenveränderungen, erhöhter Augeninnendruck, Gesichtsfelddefekte und schließlich das Alter und die Familienanamnese eines Patienten. In den letzten Jahrzehnten hielt vor allem die qualitative Messung der Papillenmorphologie und umgebender Netzhaut-Strukturen (HRT, OCT, GDX, u.a.) Einzug in die Glaukom-Diagnostik. Gemeinsam mit psychophysikalischen Tests, die Gesichtfelddefekte nachweislich vor dem Verlust an Kontrastempfindlichkeit in der Weiss-auf-Weiss-Perimetrie aufzeigen, erweitert und ergänzt sie die klassische Glaukom-Diagnostik. In dieser Arbeit konnte zunächst bestätigt werden, dass sich die Ergebnisse des Arden-Computergraphik-Farbtests bei einer erstmals großen Gruppe von Glaukom-Patienten signifikant von den Ergebnissen der Kontrollgruppe augengesunder Patienten unterscheiden. Im weiteren konnte erstmals gezeigt werden, dass auch unter Berücksichtigung des Alters und der Ergebnisse der Gesichtsfelduntersuchung ein überwiegend hochsignifikanter Zusammenhang zwischen einem funktionellen Test (Arden- Computergraphik-Farbtest) und einem modernen, rein morphologischen Test (HRT II) bei Glaukompatienten besteht. Die Einzel-Quadranten-Analyse (hier der funktionell linke untere Zusammenfassung 68 Quadrant) zeigte hier die stärksten Zusammanhänge zu den Parametern „cup area“, „rim area“, cup/disc area ratio“ und „rim/disc area ratio“ und ist dem Mittelwert der Schwellenwerte aller Quadranten überlegen. Die statistisch signifikanten Veränderungen entsprechen dem temporal-superioren Bereich der Papille, in dem in frühen und in mäßig fortgeschrittenen Glaukom-Stadien erste Verluste des neuroretinalen Randsaums zu beschrieben sind (Tuulonen A & Airaksinen PJ, 1991, Jonas JB et al., 1993). Dem Arden-Computergraphik-Farbtest kommt somit ein hoher Stellenwert in der Glaukomdiagnostik zu. Die Kombination von Funktion und Morphologie erhöht die Validität in der Glaukomdiagnostik; eine Eignung als Screening-Test, der zwischen präperimetrischen Diagnosegruppen unterscheidet, konnte allerdings nicht bestätigt werden.

Today's podcast presents a review of a psychological study of a simple screening test for Autism that can be used with infants of 12 months of age. The study presents correlational data that can be helpful for pediatricians and parents to use with infants at 12 months of age. The test is simple and harmless, but it cannot be used to defintely prove whether a child has Autism.

Die Glykogen-Speicherkrankheit (GSD) ist eine seltene Stoffwechselerkrankung, die in verschiedenen Ausprägungen (Typen) vorkommt. Im ersten Teil der Arbeit wird durch Messung der Enzymaktivität von saurer α-Glukosidase und der Enzymaktivität des Branchingenzyms ein Screening-Test durchgeführt. Im zweiten Teil wird durch Genanalyse als diagnostische Methode die Erklärung der Erkrankung auf molekulargenetischer Ebene erforscht, um den Zusammenhang zwischen dem Geno- und Phenotyp zu verstehen.